期刊文献+

某院近3年鲍曼不动杆菌耐药性变迁 被引量:7

Changes of drug resistance of Acinetobacter baumannii isolated from our hospital in recent three years
下载PDF
导出
摘要 目的分析垫江县人民医院2010~2012年鲍曼不动杆菌的耐药性变迁,为临床合理用药并有效控制鲍曼不动杆菌感染提供依据。方法针对该院2010~2012年临床分离的鲍曼不动杆菌耐药情况及患者的感染情况进行回顾性统计分析。结果鲍曼不动杆菌的临床分离率从2010年的218例(12.19%)增高到2012年的741例(18.48%)。18种抗茵药物耐药率基本都在70%以上,重症监护病房、神经科等科室出现泛耐药菌株。抗茵药物的选择性压力是细菌发生耐药性变迁的主要动因之一,年龄、基础疾病、住院时间及侵入性操作等是患者感染的高危因素。结论医院应加强医疗环境、医疗器械及医护人员的消毒,加强医院感染监测,合理使用抗菌药物等一系列措施,可有效控制鲍曼不动杆菌的感染。 Objective To analyze the changes of drug resistance of Acinetobacter baumannii in our hospital during 2010--2012 to provide reference for clinical rational drug use and the effective control of Acinetobacter baumannii infection. Methods The drug resistance of Acinetobacter baumannii clinically isolated from 2010 to 2012 and its infection situation were retrospectively performed the statistical analysis. Results The clinical isolation rate of Acinetobacter baumannii in our hospital was increased from 218 cases (12.19%) to 741 cases (18.48%) in 2012. The resistance rates of 18 kinds of antibiotics were almost more than 70%, and pan- drug-resistant Aeinetobaeter baumannii appeared in some clinical departments, such as ICU and neurology. The selective pressure of antibiotic was one of the main motive causes of drug resistance change, and age, underlying diseases, duration of hospitalization and invasive procedures were the high risk factors in patients infection. Conclusion Hospital should enhance a series of measures including reinforcing the disinfection of the medical environment, medical equipments and medical staffs, strengthening the monito- ring of hospital infection and using antibiotics rationally to reduce and control the prevalence of Acinetobacter baumannii.
出处 《重庆医学》 CAS CSCD 北大核心 2013年第26期3134-3135,3138,共3页 Chongqing medicine
关键词 鲍曼不动杆菌 药物耐受性 流行病学 Acinetobacter baumannii drug toleranc epidemiology
  • 相关文献

参考文献8

二级参考文献179

共引文献622

同被引文献64

  • 1吴旭琴,刘月秀,张险峰.社区与医院内感染细菌分布及其耐药性分析[J].苏州大学学报(医学版),2006,26(1):58-60. 被引量:6
  • 2应春妹,翁文浩.鲍曼不动杆菌多重耐药机制研究进展[J].检验医学,2007,22(2):208-212. 被引量:68
  • 3周惠芳,李军,王建源,等.ICU鲍曼不动杆菌暴发流行趋势的调查分析与控制[J].健康之路,2013,12(6):382.
  • 4Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii [J]. Nat Rev Microbiol,2007,5(12):939-951.
  • 5Munoz-Price LS, Weinstein RA. Acinetobacter infection[J]. N Engl J Med,2008,358(12) :1271-1281.
  • 6Clinical and Laboratory Standards Institute. M100 S22 Per formance standards for AntimicrobiaI susceptibility testing twenty-second informational supplement [S]. Wayne, PA, USA:CLSI,2012.
  • 7Falagas ME, Karveli EA, Kelesidis I, et al. Community-ac- quired Acinetobaeter infections[J]. Eur J Clin Microbiol Infect Dis,2007,26(12) :857 868.
  • 8Dexter C, Murray GL, Paulsen IT, et al. Community-ac- quired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis[J]. Expert Rev Anti Infect Ther, 2015,13 (5) : 567-573.
  • 9Viehman JA, Nguyen MH, Doi Y. Treatment Options for carbapenern resistant and extensively drug-resistant Acin- etobacter baumannii infections[J].Drugs, 2014,74 ( 12 ) : 1315-1333.
  • 10Shin JA, Chang YS, Kim HJ, et al. Clinical outcomes of tigecycline in the treatment of multidrug resistant Acine- tobacter baumannii infection[J]. Yonsei Med J, 2012,53 (5) :974-984.

引证文献7

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部